Wealth Enhancement Advisory Services LLC Boosts Stock Holdings in Insulet Corporation $PODD

Wealth Enhancement Advisory Services LLC raised its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 10.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 3,332 shares of the medical instruments supplier’s stock after purchasing an additional 304 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Insulet were worth $1,003,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT purchased a new position in Insulet during the 1st quarter valued at about $26,000. Larson Financial Group LLC grew its position in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares during the last quarter. SouthState Corp grew its position in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in shares of Insulet in the 1st quarter worth approximately $53,000. Finally, NewEdge Advisors LLC grew its position in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 64 shares during the last quarter.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $305.98 on Thursday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12 month low of $225.37 and a 12 month high of $353.50. The company has a 50 day simple moving average of $320.45 and a two-hundred day simple moving average of $297.85. The stock has a market cap of $21.54 billion, a price-to-earnings ratio of 93.00, a PEG ratio of 2.56 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same period in the previous year, the business posted $0.55 EPS. The business’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of analyst reports. Citigroup reaffirmed a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Royal Bank Of Canada lifted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Truist Financial started coverage on shares of Insulet in a research report on Monday, June 16th. They issued a “buy” rating and a $365.00 price objective on the stock. Finally, Oppenheimer lifted their target price on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $345.47.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.